A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Public ClinicalTrials.gov record NCT01320085. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600 or NRAS Mutations
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.
Study identification
- NCT ID
- NCT01320085
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 183 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 24, 2011 (Actual)
- Primary completion
- Jan 7, 2014 (Actual)
- Completion
- Feb 6, 2023 (Actual)
- Last update posted
- Jan 24, 2024
2011 – 2023
United States locations
- U.S. sites
- 10
- U.S. states
- 4
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72703-4005 | — |
| H. Lee Moffitt Cancer Center & Research Institute, Inc. | Tampa | Florida | 33612 | — |
| OHSU Knight Cancer Institute | Portland | Oregon | 97201 | — |
| OHSU Center for Health and Healing | Portland | Oregon | 97239 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Cancer Care Associates Medical Oncology | Allentown | Pennsylvania | 18104 | — |
| St. Luke's Cancer Center - Allentown Campus | Allentown | Pennsylvania | 18104 | — |
| Cancer Care Associates Medical Oncology | Bethlehem | Pennsylvania | 18015 | — |
| St. Luke's University Health Network | Bethlehem | Pennsylvania | 18015 | — |
| St. Luke's Hospital - Quakertown Campus | Quakertown | Pennsylvania | 18951 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01320085, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 24, 2024 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01320085 live on ClinicalTrials.gov.